Orap
NDC Package 57844-151-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Orap is a medication used to reduce uncontrolled movements (motor tics) or outbursts of words/sounds (vocal tics) caused by Tourette syndrome. Marketed by Teva Select Brands, this product is identified by NDC 57844-151 and is authorized under FDA application NDA017473.

Identification & Billing

NDC Package Code
57844-151-01
Package Description
100 TABLET in 1 BOTTLE
Product Code
57844-151
11-Digit Billing Format
57844015101
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA

Clinical Specifications

Proprietary Name
Orap
Dosage Form
-
Usage Information
This medication is used to reduce uncontrolled movements (motor tics) or outbursts of words/sounds (vocal tics) caused by Tourette syndrome. Pimozide is a medication that works by decreasing the activity of a natural substance (dopamine) in the brain. Pimozide should not be used for mild symptoms. It should only be used if symptoms cause severe problems in everyday life and other medicines or treatments have not been effective.

Regulatory & Marketing

Labeler Name
Teva Select Brands
FDA Application #
NDA017473
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-07-2000
End Marketing Date
04-11-2019
Listing Expiration
04-11-2019
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 57844-151-01 identifies a specific commercial package of 100 tablet in 1 bottle of Orap, labeled by Teva Select Brands. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Teva Select Brands on June 07, 2000. The current certification is valid through April 11, 2019.

What are the primary indications for this medication?

This medication is used to reduce uncontrolled movements (motor tics) or outbursts of words/sounds (vocal tics) caused by Tourette syndrome. Pimozide is a medication that works by decreasing the activity of a natural substance (dopamine) in the brain. Pimozide should not be used for mild symptoms. It should only be used if symptoms cause severe problems in everyday life and other medicines or treatments have not been effective.

How is this Teva Select Brands product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 57844015101. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
57844-151-01
11-Digit CMS (5-4-2)
57844-0151-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.